Company / SG&A per Share
Syndax Pharmaceuticals Inc SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$2.10
FY2025
5-year range
$0.34 / $2.10
FY2021-FY2025
Trend
+47.1%
vs FY2024
Sector context
#79 of 210
Health Care
What the data says
At $2.10, Syndax Pharmaceuticals Inc's sg&a per share ranks #132 of 210 in the Health Care sector. SG&A per Share has increased for 4 consecutive years, from $0.34 in FY2021 to $2.10 in FY2025.
Based on SEC 10-K filings.
2.10 in FY2025 with a 5-year CAGR of +26.9%.
Increased from $0.98 to $2.10 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +51.3%
- 5-Year CAGR
- +26.9%
- 10-Year CAGR
- -
Sector benchmark
#132 of 210 in Health CareTop 62% of 210This company $2.10 Sector average $40.75
▼
-94.9% below sector average
Key checks
Key Insights
- Syndax Pharmaceuticals Inc's sg&a per share has grown for 4 consecutive years.
- In FY2025, sg&a per share increased 47.1% year-over-year.
- Ranks #79 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.10 | +47.1% |
| FY2024 | $1.43 | +45.0% |
| FY2023 | $0.98 | +62.4% |
| FY2022 | $0.60 | +80.3% |
| FY2021 | $0.34 | -47.3% |
| FY2020 | $0.64 | -0.3% |
| FY2019 | $0.64 | +16.9% |
| FY2018 | $0.55 | -14.2% |
| FY2017 | $0.64 | -99.5% |
| FY2016 | $130.58 | -23.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026